1. Biogen Acquires Apellis for $5.6B in Major Immunology and Rare Disease Play
Biogen has made a decisive $5.6 billion move to acquire Apellis Pharmaceuticals, marking one of its largest-ever acquisitions. The deal is a strategic pivot to significantly expand Biogen's portfolio in immunology and rare disease treatments, signaling a major investment in a high-value therapeutic area. This acquisiti...